JP2023516936A5 - - Google Patents
Info
- Publication number
- JP2023516936A5 JP2023516936A5 JP2022551318A JP2022551318A JP2023516936A5 JP 2023516936 A5 JP2023516936 A5 JP 2023516936A5 JP 2022551318 A JP2022551318 A JP 2022551318A JP 2022551318 A JP2022551318 A JP 2022551318A JP 2023516936 A5 JP2023516936 A5 JP 2023516936A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pvrig
- cancer
- tigit
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010174835.4 | 2020-03-13 | ||
| CN202010174835 | 2020-03-13 | ||
| PCT/CN2021/080470 WO2021180205A1 (zh) | 2020-03-13 | 2021-03-12 | Pvrig结合蛋白及其医药用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516936A JP2023516936A (ja) | 2023-04-21 |
| JP2023516936A5 true JP2023516936A5 (enExample) | 2024-04-26 |
| JP7705873B2 JP7705873B2 (ja) | 2025-07-10 |
Family
ID=77672140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551318A Active JP7705873B2 (ja) | 2020-03-13 | 2021-03-12 | Ｐｖｒｉｇ結合タンパク質及びその医薬用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12617852B2 (enExample) |
| EP (1) | EP4119162A4 (enExample) |
| JP (1) | JP7705873B2 (enExample) |
| KR (1) | KR20220154140A (enExample) |
| CN (1) | CN115003333B (enExample) |
| CA (1) | CA3170025A1 (enExample) |
| TW (1) | TWI873311B (enExample) |
| WO (1) | WO2021180205A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240376207A1 (en) * | 2021-09-15 | 2024-11-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody |
| TW202327649A (zh) * | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白聯合免疫檢查點抑制劑用於治療癌症 |
| CN115819582B (zh) * | 2021-12-24 | 2026-07-17 | 合肥天港免疫药物有限公司 | Pvrig的抗体或其抗原结合片段及其应用 |
| CN116925233A (zh) | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
| CN116925222A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| CN119487079A (zh) * | 2022-06-08 | 2025-02-18 | 山东先声生物制药有限公司 | 一种pvrig/tigit双特异性抗体药物组合物及其用途 |
| WO2024027824A1 (zh) * | 2022-08-05 | 2024-02-08 | 上海君实生物医药科技股份有限公司 | 抗cd112r抗体药物组合物及其用途 |
| CN120112553A (zh) * | 2022-08-10 | 2025-06-06 | 广州百济神州生物制药有限公司 | 抗pvrig抗体和使用方法 |
| US20260116967A1 (en) * | 2022-08-31 | 2026-04-30 | CSPC Megalith Biopharmaceutical Co., Ltd. | Anti-pvrig antibody and application thereof |
| CN120187755A (zh) * | 2022-11-10 | 2025-06-20 | 华辉安健（北京）生物科技有限公司 | 抗cd112r抗体及其用途 |
| EP4681729A4 (en) * | 2023-03-15 | 2026-07-15 | Shanghai Mabgen Biotech Ltd | PHARMACEUTICAL COMPOSITION CONTAINING A PD-1/PVRIG/TIGIT BINDING PROTEIN AND ITS MEDICAL USE |
| AU2024283832A1 (en) * | 2023-06-06 | 2026-01-29 | WuXi Biologics Ireland Limited | Anti-pvrig antibodies and uses thereof |
| TW202523352A (zh) * | 2023-09-20 | 2025-06-16 | 大陸商來凱醫藥科技（上海）有限公司 | 抗ｐｖｒｉｇ或ｔｉｇｉｔ的抗體、由其構建的雙特異性抗體、其製備方法和用途 |
| WO2025108395A1 (zh) * | 2023-11-23 | 2025-05-30 | 广东菲鹏制药股份有限公司 | 抗人pvrig抗体及其应用 |
| CN119841952B (zh) * | 2023-12-22 | 2025-11-04 | 华润生物医药有限公司 | 抗pvrig抗体及其用途 |
| CN120230207A (zh) * | 2023-12-29 | 2025-07-01 | 百奥泰生物制药股份有限公司 | Pvrig结合蛋白、双特异性抗体及其应用 |
| CN122071526A (zh) * | 2024-11-21 | 2026-05-22 | 广东菲鹏制药股份有限公司 | Pvrig结合分子及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8192474B2 (en) * | 2006-09-26 | 2012-06-05 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
| WO2009126688A2 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| TWI888366B (zh) | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| KR20170017916A (ko) | 2014-05-13 | 2017-02-15 | 추가이 세이야쿠 가부시키가이샤 | 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자 |
| CA2957722C (en) | 2014-08-19 | 2022-05-31 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| AR103268A1 (es) | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| IL254039B2 (en) * | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| US10550173B2 (en) * | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
| CN115925931A (zh) | 2015-08-14 | 2023-04-07 | 默沙东公司 | 抗tigit抗体 |
| SG10202007764TA (en) | 2015-09-25 | 2020-09-29 | Genentech Inc | Anti-tigit antibodies and methods of use |
| WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
| KR102585976B1 (ko) | 2016-08-17 | 2023-10-05 | 컴퓨젠 엘티디. | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 |
| JP7348072B2 (ja) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
| CN111051347B (zh) | 2017-09-29 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | Tigit抗体、其抗原结合片段及医药用途 |
| SG11202011461TA (en) * | 2018-06-01 | 2020-12-30 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
| CN115769181B (zh) | 2021-04-23 | 2025-10-10 | 京东方科技集团股份有限公司 | 一种解锁控制方法、装置、电子设备和计算机可读存储介质 |
| US20240343803A1 (en) * | 2021-07-30 | 2024-10-17 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof |
| US12076062B2 (en) * | 2021-08-04 | 2024-09-03 | Kuwait University | Modular intramedullary fixation devices |
| US20240376207A1 (en) * | 2021-09-15 | 2024-11-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody |
| TW202327649A (zh) * | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白聯合免疫檢查點抑制劑用於治療癌症 |
| JP2024535793A (ja) * | 2021-09-15 | 2024-10-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用 |
-
2021
- 2021-03-12 EP EP21768888.6A patent/EP4119162A4/en active Pending
- 2021-03-12 CA CA3170025A patent/CA3170025A1/en active Pending
- 2021-03-12 JP JP2022551318A patent/JP7705873B2/ja active Active
- 2021-03-12 CN CN202180010585.3A patent/CN115003333B/zh active Active
- 2021-03-12 WO PCT/CN2021/080470 patent/WO2021180205A1/zh not_active Ceased
- 2021-03-12 KR KR1020227034534A patent/KR20220154140A/ko active Pending
- 2021-03-12 TW TW110108958A patent/TWI873311B/zh active
- 2021-03-12 US US17/905,694 patent/US12617852B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109963592B (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| BR112019025188A2 (pt) | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos | |
| JP2026079825A (ja) | 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害 | |
| JP2022523740A (ja) | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 | |
| CN110882385A (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| BR112020013144A2 (pt) | Terapia de combinação com anticorpos anti-il-8 e anti-corpos anti-pd-1 para tratamento do câncer | |
| CN108778332B (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| JP5220315B2 (ja) | 抗ＥｐＣＡＭ免疫グロブリン | |
| CA3110276A1 (en) | Treatment of triple negative breast cancer with targeted tgf-b inhibition | |
| BR112021010999A2 (pt) | Uso de anticorpo pd-l1 de articulação do complexo de proteína il-15 para tratamento de doenças tumorais | |
| WO2020211804A1 (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| CN120344271A (zh) | 抗her2抗体药物偶联物治疗乳腺癌 | |
| CN111629731A (zh) | 治疗癌症的组合物和方法 | |
| WO2021160151A1 (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| CN113018429A (zh) | 治疗卵巢癌的药物组合 | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 | |
| TW202028248A (zh) | 使用抗ｃｄ１２３免疫結合物之治療方法 | |
| EP4516314A1 (en) | Combination of anti-pd-1 antibody and anti-egfr antibody, and use thereof in treatment of head and neck squamous cell carcinoma | |
| WO2024183622A1 (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| WO2023134787A2 (zh) | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 | |
| TWI619728B (zh) | Ｇｉｓｔ之治療 | |
| CN117815387A (zh) | Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物 | |
| WO2021180027A1 (zh) | 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法 | |
| CN120695174A (zh) | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 | |
| JP2023509083A (ja) | 腫瘍を予防又は治療するための薬物の調製における抗ｃｄ４７抗体と抗ｃｄ２０抗体の組み合わせの使用 |